Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

PP405 might take 3-4 years to be available, but some claim Everychem offers a similar product, though its effectiveness is debated. Users discuss the risks of using untested grey market products and the potential for adverse effects.

Breezula is seen as potentially overhyped, with concerns about its cost, effectiveness, and long-term benefits compared to existing treatments like finasteride and minoxidil. Some users believe it could complement existing treatments, while others are skeptical about its impact and prefer waiting for newer options like GT20029 and PP405.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

Creatine may increase DHT levels, potentially causing symptoms like acne, oily hair, and hair shedding. Users report mixed experiences, with some avoiding creatine due to hair loss concerns and others seeing no impact.

Creatine may increase DHT levels, potentially causing hair loss in some people, though experiences vary. Treatments like finasteride or minoxidil are suggested to manage potential hair loss.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

Kintor 0.9% is not effective for hair regrowth or thickening and may cause testicle sensitivity. The conversation criticizes the hype around Kintor and discusses the ineffectiveness of pyrilutamide compared to other treatments like RU58841, finasteride, and minoxidil.

Finasteride may be losing effectiveness for the user after 4.5 years, possibly due to intense workouts or a synchronized hair shedding cycle. Suggestions include switching to Dutasteride or continuing with Finasteride while considering a hair transplant for hairline density.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

PP405 is a new hair loss treatment facing mixed reactions due to initial hype and insufficient data. Some are hopeful, but many doubt its effectiveness compared to minoxidil and finasteride.

A user plans to switch from finasteride to dutasteride for better hair loss treatment, citing dutasteride's higher DHT suppression. Others share mixed experiences, discussing transition methods, shedding, and potential side effects.

A 22-year-old male has been using oral finasteride for a year with no improvement in hair loss and was denied dutasteride by a dermatologist due to FDA approval issues but was prescribed oral minoxidil instead. The user is seeking advice on whether to switch to dutasteride, continue finasteride, or add minoxidil.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

Many users criticize advice on forums that suggest shaving heads instead of trying treatments like finasteride for hair loss. They argue that maintaining hair is important for self-esteem and dating success, and that baldness often requires compensating with other attributes.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

The conversation is optimistic about future hair loss treatments, highlighting Veradermics, Breezula, and PP405 as promising options expected by 2027-2028. The user expresses hope that these developments will prevent future generations from experiencing the same struggles with hair loss.

Redensyl is a plant-based treatment that may support hair regrowth by reactivating dormant follicles and improving hair density, especially in early-stage thinning. It is not a miracle cure and results vary; it is less proven than Minoxidil or Finasteride and may cause scalp irritation.

A new drug, PP405, is being discussed as a potential cure for baldness, with hopes it could be more effective than Minoxidil and Finasteride. Users are skeptical about its effectiveness and the need for lifelong use.

Switching to Dutasteride worsened hair condition, causing shedding and inflammation. The user will continue Dutasteride until 18 months before possibly switching back to Finasteride, while using oral Minoxidil.

Minoxidil and LLLT are compared for treating hair loss, with LLLT showing higher regrowth rates and fewer side effects. LLLT is less time-consuming and more suitable for those with health issues, while Minoxidil requires daily application.

A 37-year-old male has been using finasteride for 5 years and dutasteride for 9 months to address hair loss, noticing improvements but also some recent thinning. He experienced no significant side effects from either treatment, except a slight decrease in semen volume with dutasteride, and is considering trying oral minoxidil again despite previous side effects.

Creatine at 2.5 g/day did not affect DHT levels in the user, suggesting it may not cause hair loss through DHT. The user used minoxidil during the experiment but did not use finasteride or other DHT-reducing medications.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

A user discussed their experience with finasteride for almost 2 years and oral minoxidil for 7 months, noting thicker follicles but no change in density. Replies suggested getting a shorter haircut to make the hair look thicker and healthier.

OP switched from finasteride to dutasteride due to hair loss, but after 5 months, they are experiencing diffuse thinning and scalp issues. They are considering additional treatments like RU58841 and are using minoxidil, essential oils, and keto shampoo to manage symptoms.